text_1: New Chemo Drug May Benefit Some Breast Cancer Patients
text_2: The article clearly details the survival benefit of eribulin, but it fails to tell readers that the drug has been approved in the United States. It also fell short because it did not explain how much the drug costs or how often harms occurred in the study. Metastatic breast cancer becomes progressively more difficult to treat as various therapies become less effective. This study suggests that eribulin is the first single-agent chemotherapy that extended the survival time of women with metastatic breast cancer who had already been treated with two to five other chemotherapies. This study is likely to generate significant interest and may change clinical practice for metastatic patients.